Replies to post #69201 on PharmaCyte Biotech Inc (PMCB)

[rudygerner]

You nailed it JJ. PMCB has no competition because this technology is completely bioinert inside the human body for up to two years, possibly longer. Couple that with this technology's ability to be cryopreserved and shipped around the world and the summation is a premier treatment for diabetes - basically a cure for diabetes.

This technology is patented and PharmaCyte's IP portfolio is continually being strengthened exactly for the reasons listed above.
http://ir.pharmacytebiotech.com/press-releases/detail/109/as-diabetes-becomes-global-epidemic-pharmacyte-biotechs
http://ir.pharmacytebiotech.com/press-releases/detail/89/pharmacyte-biotech-discusses-protection-strategy-for-cancer

[DragonBear]

Then you have absolutely nothing to worry about..... right?

Conditional not required.

So they have competition? Where?
Sorry, wrong! Not for this type of delivery platform.

CIAB is no longer on patent. So indeed where is the competition???

What's the evidence CIAB has any additive effect to Metronomic Ifosfamide therapy alone? Answer: There is none.

What percent of the Ifosfamide is converted by the 200K cells inside CIAB vs approx 4.5B liver cells? Any animal data?